The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
Consolidated revenue from operations stood at Rs. 111.05 crore
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Subscribe To Our Newsletter & Stay Updated
